Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
D007153 | Immunologic Deficiency Syndromes NIH | 0.41 |
D000077062 | Burnout, Psychological NIH | 0.23 |
Navigate: Correlations HPO
There is one clinical trial.
This study aims to: - Demonstrate the efficacy of a 2-dose schedule of CVnCoV in the prevention of first episodes of virologically-confirmed cases of COVID-19 of any severity in SARS-CoV-2 naïve participants. - Demonstrate the efficacy of a 2-dose schedule of CVnCoV in the prevention of first episode of virologically-confirmed moderate to severe cases of COVID-19 in SARS-CoV-2 naïve participants.
Description: Seroconversion is defined as detectable SARS-CoV-2 N protein antibodies in the serum of asymptomatic seronegative participants who tested seronegative on Day 1 and on Day 43.
Measure: Number of participants with seroconversion to the nucleocapsid (N) protein of SARS-CoV-2 ≥ 15 days after the second study vaccination Time: Days 1, 43, 211 and 393Description: S protein will be measured by enzyme-linked immunosorbent assay (ELISA).
Measure: Number of participants with serum antibodies to SARS-CoV-2 spike (S) protein Time: Days 1, 29, 43, 57, 120, 211 and 393Description: S protein will be measured by enzyme-linked immunosorbent assay (ELISA). Seroconversion is defined as detectable SARS-CoV-2 S protein antibodies in the serum of participants who tested seronegative on Day 1.
Measure: Number of participants who experience seroconversion to SARS-CoV-2 spike (S) protein Time: Days 1, 29, 43, 57, 120, 211 and 393Description: Serum vital neutralizing antibodies to SARS-CoV-2 virus will be measured by a viral neutralizing antibody assay.
Measure: Number of participants with serum vital neutralizing antibodies to SARS-CoV-2 virus Time: Days 1, 29, 43, 57, 120, 211 and 393Description: Seroconversion to SARS-CoV-2 virus will be measured by a viral neutralizing antibody assay. Seroconversion is defined as detectable SARS-CoV-2 viral neutralizing antibodies in the serum of participants who tested seronegative on Day 1.
Measure: Number of participants who experience seroconversion to SARS-CoV-2 virus Time: Days 1, 29, 43, 57, 120, 211 and 393Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports